Cempra Inc. (Nasdaq: CEMP) reported upbeat results from a Phase 3 study of oral fusidic acid to treat patients with acute bacterial skin and skin structure infections. Shares of the pharmaceutical climbed 90 cents to close at $4.05.
Cempra reports positive study results
February 24, 2017 at 17:47 PM EST
